Medical devices, healthcare technology and the business of care
COMPANY INTELLIGENCE

Biotronik AG

Explore this company’s associated devices, FDA decisions and regulatory history.

Clinical monitoring equipment, editorial photography

Biotronik AG

Regulatory records
6
Linked recall entries
0
Headquarters
Not reported
Brand website
Not reported
COMPANY INTELLIGENCE

What the linked records show

MedtechLedger currently links 6 FDA records to the applicant name Biotronik AG. It includes 3 original PMA approvals. 3 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.

The dated entries run from Dec 17, 2015 to Sep 24, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.

Product code NIO appears in 2 of the 6 linked filings. The collection spans 3 FDA product codes and 3 original PMA application families. These figures describe the filings available here; they do not establish the company’s total device sales or market share.

The largest PMA family in this collection is P140030, with 2 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 6 linked filings have a current plain-language explanation checked against the recorded FDA decision.

Applicant mailing address recorded by FDA: Ackerstrasse 6, Bülach, 8180. Recorded on P170030/S066, decision dated Sep 24, 2026.

Changes described in PMA records

P170030/S066: ORSIRO Sirolimus Eluting Coronary Stent System

The FDA recorded a 30-Day Notice decision, OK30, dated 2026-09-24, for the ORSIRO Sirolimus Eluting Coronary Stent System under application P170030/S066, submitted by Biotronik AG. The product is a coronary drug-eluting stent in the cardiovascular specialty, product code NIQ. The supplement type is a 30-Day Notice, and the recorded reason is a process change affecting manufacturer, sterilizer, packager or supplier.

The stated scope is changes to solvent preparation and drug coating application. This entry covers that manufacturing process change within the existing P170030 application; it is not a new approval of the whole stent system, and the source does not describe clinical data, coating specifications or the effect on finished-device performance. The source also does not include the decision documents, so the review basis behind OK30 remains unknown from this record.

FDA approval-order wording

changes to solvent preparation and drug coating application

Sep 24, 2026 · 30-Day Notice

P160025/S026: Pulsar-18 T3 Peripheral Self-Expanding Nitinol Stent System

The FDA record for P160025/S026, dated 2026-09-11 and marked OK30, is a 30-day notice supplement to the Pulsar-18 T3 Peripheral Self-Expanding Nitinol Stent System PMA. The listed change is "modifications to the Gold-plating manufacturing equipment" and is categorized as a process change involving a manufacturer, sterilizer, packager or supplier. The stent's device category is superficial femoral artery stent (product code NIP, cardiovascular specialty), with Biotronik AG as applicant.

The S026 supplement number ties this filing to the original P160025 approval, but it does not constitute approval of the whole stent system, and a manufacturing notice is not an original PMA. The record states a purpose — equipment modification — without specifying which equipment, what the modifications were, or any supporting validation. The database entry provides no evidence of safety or clinical effectiveness; that reported purpose should not be read as such proof.

Several details remain absent: the equipment's identity, the nature and extent of the modification, the affected manufacturing step, and any performance data. Researchers should treat the entry as a notice of a process change and not infer an indication change, a trial, or a clinical outcome.

FDA approval-order wording

modifications to the Gold-plating manufacturing equipment

Sep 11, 2026 · 30-Day Notice

P140030/S025: Astron Peripheral Self-Expanding Nitinol Stent System

The FDA database lists decision OK30 on 2026-09-11 for P140030/S025, a 30-Day Notice supplement to the Astron Peripheral Self-Expanding Nitinol Stent System PMA (P140030). The applicant is Biotronik AG, and the supplement reason is recorded as a process change affecting manufacturer, sterilizer, packager or supplier, with device category STENT, ILIAC and product code NIO.

The stated scope is modifications to the Gold-plating manufacturing equipment. The record does not identify which equipment, what the modification was, or how it relates to stent production, so those specifics remain unknown. The S025 identifier ties the filing to the existing P140030 PMA rather than a new system approval, and the stated purpose of the notice is not independent evidence of safety or clinical effectiveness.

The decision code OK30 and the September 2026 date are as recorded in the supplied database fields; the entry provides no further rationale, review detail or outcome description beyond that code and date.

FDA approval-order wording

modifications to the Gold-plating manufacturing equipment

Sep 11, 2026 · 30-Day Notice

P170030: ORSIRO Sirolimus Eluting Coronary Stent System

FDA approved the Orsiro Sirolimus Eluting Coronary Stent System from Biotronik AG on February 22, 2019. The approval record states the device is indicated for improving coronary luminal diameter in patients with symptomatic heart disease, stable angina, unstable angina, non-ST elevation myocardial infarction, or documented silent ischemia due to atherosclerotic lesions in native coronary arteries.

The stated indication includes patients with diabetes mellitus and specifies a reference vessel diameter of 2.25 mm to 4.0 mm and a lesion length of less than 36 mm. The record does not contain a supplement type or supplement reason, and no clinical effectiveness data or trial information is provided in the source fields.

FDA approval-order wording

Approval of the Orsiro Sirolimus Eluting Coronary Stent System. This device is indicated for improving coronary luminal diameter in patients, including those with diabetes mellitus, with symptomatic heart disease, stable angina, unstable angina, non-ST elevation myocardial infarction or documented silent ischemia due to atherosclerotic lesions in the native coronary arteries with a reference vessel diameter of 2.25 mm to 4.0 mm and a lesion length of < 36 mm.

Feb 22, 2019

P160025: ASTRON PULSAR STENT SYSTEM, PULSAR-18 STENT SYSTEM

FDA approved PMA P160025 for the Astron Pulsar Stent System and Pulsar-18 Stent System on March 23, 2017. The applicant is Biotronik AG, and the product code is NIP under the specialty Cardiovascular.

The stated indication is improving luminal diameter in patients with symptomatic de novo, restenotic or occlusive lesions in the superficial femoral or proximal popliteal arteries, with reference vessel diameters from 3.0 to 6.0mm and total lesion lengths up to 190mm. The source statement reports an intended purpose, not independent proof of safety or clinical effectiveness.

FDA approval-order wording

Approval for the Astron Pulsar Stent System and Pulsar-18 Stent System. These devices are indicated for use to improve luminal diameter in patients with symptomatic de novo, restenotic or occlusive lesions located in the superficial femoral or proximal popliteal arteries, with reference vessel diameters from 3.0 to 6.0mm and total lesion lengths up to 190mm.

Mar 23, 2017

Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.

Devices & associated records

Product / regulatory recordCompanyPathwayDecision dateSource
Biotronik AGPMA supplementSep 24, 2026FDA
Biotronik AGPMA supplementSep 11, 2026FDA
Biotronik AGPMA supplementSep 11, 2026FDA
Biotronik AGPMA approvalFeb 22, 2019FDA
Biotronik AGPMA approvalMar 23, 2017FDA
Biotronik AGPMA approvalDec 17, 2015FDA
Source information

Source updated Nov 9, 2026. Retrieved Nov 19, 2026.